Aranesp Extended Dosing Approval Could Provide Advantage Over Procrit In Chemo Market
FDA clears a supplemental BLA for every-three-week dosing of darbepoetin alfa in chemotherapy-induced anemia patients.
FDA clears a supplemental BLA for every-three-week dosing of darbepoetin alfa in chemotherapy-induced anemia patients.